About Leinco Technologies
Leinco Technologies is a Healthcare company based in St. Louis (United States) founded in 1992, and was acquired by Ampersand Capital in November 2021. Manufacturer of antibodies, proteins, reagents, and kits for life science research. Leinco Technologies has completed 1 acquisition, including QED Bioscience. Its website leinco.com draws about 25 thousand monthly visits. Leinco Technologies offers products and services including Antibodies, Proteins, and Custom Services. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and Drug Development. Its legal entity is Leinco Technologies, Inc. Its competitors include GenScript, Epitomics and Vector Laboratories; 2 of its 3 listed competitors have raised funding.
Company details
Leinco Technologies was founded in 1992 in St. Louis, United States, and operates within the life science research sector. Antibodies, proteins, in vitro diagnostic products, buffers, and reagents are produced and supplied, organized by research area, application, and antigen. Custom services are offered, including antibody development, cell line creation, protein production, lyophilization, and conjugation processes.
- Headquarters St. Louis, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website leinco.com
- Social LinkedIn X Facebook
- Acquired by Ampersand Capital (Nov 2021)
- Legal Name Leinco Technologies, Inc.
- Latest Funding Round$1M (USD), Grant
Feb 2025
- InvestorsGates Foundation
& 1 more
- Investments & Acquisitions
- Acquired byAmpersand Capital
(Nov 2021)
Products & Services of Leinco Technologies
Leinco Technologies offers a comprehensive portfolio of products and services, including Antibodies, Proteins, and Custom Services.
High-quality antibodies for scientific and diagnostic applications
Recombinant proteins supporting life sciences research studies
Tailored antibody and protein production for research needs
Funding Insights of Leinco Technologies
- Total Rounds 1
- Last Round Grant — $1M
- First Round $1M
(Feb 2025)
- Investors Count 1
All 1 funding rounds of Leinco Technologies with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $1M | Grant | – | – |
2 investors in total: 2 institutional.
Investors in Leinco Technologies
Leinco Technologies has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation and Ampersand Capital Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Ampersand Capital Partners is focused on investments in healthcare and life sciences. | ampersandcapital.com | Boston, United States | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for Leinco Technologies
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Leinco Technologies
4 people are tracked at Leinco Technologies (3 in leadership, 1 in team).
| Name | Role | Group |
|---|---|---|
Ryan Griffith | Director Of Sales | Leadership |
W. Pat Leinert Sr. | President and CEO | Leadership |
Michael J. Dishian | Chief Financial Officer | Leadership |
Robert Stobezki, PhD | R&D Manager | Team |
Complete people profiles for Leinco Technologies
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Leinco Technologies
Leinco Technologies has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include QED Bioscience.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Proteins and antibody reagents for research | qedbio.com | San Diego, United States | 1997 | Sep 2024 | •••• |
Complete acquisition details for Leinco Technologies
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Leinco Technologies
4 dated milestones of Leinco Technologies across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Leinco Technologies is founded.
- Exit Acquired by Ampersand Capital.
- Acquisition Acquires QED Bioscience.
- Funding First funding round of $1.0M.
Competitors of Leinco Technologies
Leinco Technologies has 3 listed competitors in our database, 2 of them funded. They include GenScript, Epitomics and Vector Laboratories.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| genscript.com | 2002 | Piscataway, United States | $15M | 5,260 | Reagents and instruments are provided for life sciences research. | |
| epitomics.com | 2001 | Burlingame, United States | $16.21M | Monoclonal antibody technology and products are developed by Epitomics. | ||
| vectorlabs.com | 1976 | Burlingame, United States | Labeling and detection reagents immunohistochemistry studies and other life science research applications |
Detailed competitors of Leinco Technologies
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Leinco Technologies
The website of Leinco Technologies (leinco.com) receives about 24.9K visits a month.
- Monthly visits24.9K
▲ 26.6% vs previous month
Websites whose visitors overlap most with Leinco Technologies. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| proteinbiotechnologies.com | 100% | View details | |||
antibody-creativebiolabs.com | antibody-creativebiolabs.com | 96% | #2,485,914 | – | |
a.abcam.com | a.abcam.com | 90% | – | ||
| meridianlifescience.com | 87% | #11,146,867 | View details | ||
| mainebiotechnology.com | 87% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 31 similar websites and full traffic analytics for Leinco Technologies
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 31 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Biopharma Outsourcing & Drug Delivery
3 companies that operate in the same segment as Leinco Technologies (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Suite solutions are provided for payers and healthcare providers. | 1998 | Princeton, New Jersey, United States | USD 220 M | USD 374.1 M | 4,490 | |
Wearable insulin infusion systems are developed for diabetes patients. | 2000 | Boston, Massachusetts, United States | USD 120.4 M | USD 2.71 B | 3,900 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Leinco Technologies
Complete news archive for Leinco Technologies
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Leinco Technologies
Leinco Technologies was founded in 1992 and raised its 1st funding round 33 years after it was founded.
Leinco Technologies is headquartered in St. Louis, United States. It is registered at St. Louis, Missouri, United States.
Leinco Technologies was founded in 1992 in St. Louis, United States, and operates within the life science research sector. Antibodies, proteins, in vitro diagnostic products, buffers, and reagents are produced and supplied, organized by research area, application, and antigen. Custom services are offered, including antibody development, cell line creation, protein production, lyophilization, and conjugation processes.
Leinco Technologies's top competitors include GenScript, Epitomics and Vector Laboratories.
Leinco Technologies offers Antibodies, Proteins, and Custom Services.
Leinco Technologies has made 1 acquisition, including QED Bioscience.
Leinco Technologies has 2 investors. Key investors include Gates Foundation, and Ampersand Capital Partners.
Leinco Technologies operates through Leinco Technologies, Inc..
Yes. Leinco Technologies was acquired by Ampersand Capital in November 2021.